Sigma Capital

28-07-2025

Today…Listing the Capital Increase for Egyptian International ‎Pharmaceutical Industries – EIPICO

Source: MIST

Announcement Subject: Registration of an increase in authorized capital, ‎an increase in issued and paid-up capital, and an amendment to the head ‎office and legal domicile.‎

Company Name: Egyptian International Pharmaceutical Industries - EIPICO

ISIN: EGS38081C013‎

Announcement Format:‎

The Securities Listing Committee, in its meeting held on July 23, 2025, ‎approved the following:‎

First: Registration of an increase in the authorized capital of Egyptian ‎International Pharmaceutical Industries - EIPICO, from EGP 1.5 billion to ‎EGP 6 billion.‎

Second: Registration of shares of the increase in the issued and paid-up ‎capital of Egyptian International Pharmaceutical Industries - EIPICO. ‎EIPICO, from EGP 1,487,557,500 to EGP 1,687,557,500, an increase of ‎EGP 200 million, distributed over 20 million shares. The subscription for ‎the increased shares was at a fair value of EGP 50 per share, representing ‎EGP 10 per share as a nominal value, plus an issuance premium of EGP 40 ‎per share totaling EGP 800 million, to be transferred to the reserve ‎account. The increase was paid by means of a bank deposit certificate ‎through cash subscriptions by existing shareholders. This increase ‎represents the eleventh issue, as listed on the Egyptian Securities Listing ‎Table (shares).‎

Note that:‎

‎? The subscription rights for the Egyptian International Pharmaceutical ‎Industries Company have been registered. EIPICO-2, separate from the ‎company's original share, will be available for trading from Sunday, ‎January 26, 2025 (the subscription opening date) until Wednesday, ‎February 19, 2025 (three business days before the subscription closing ‎date).‎

The subscription rights were not listed on the database and were not ‎traded, as the share market price did not exceed the subscription price.‎

On October 24, 2024, the Disclosure Sector published the company's fair ‎value study issued by the independent financial advisor, Eagle Financial ‎Consulting.‎

Third: The company's shares, after the cash increase, will be listed on the ‎database, effective from the start of the trading session on Monday, July ‎‎28, 2025, as follows:‎

‎(p. 1: p. 11) 168,755,750 shares‎

Fourth: The head office and legal domicile of Egyptian International ‎Pharmaceutical Industries Company are being amended. EBEICO, in light ‎of amending Article (4) of the company’s articles of association by adding ‎the land of EBEICO 3 factory as the location of the activity, so that Article ‎‎(4) after the amendment becomes as follows: - The company’s ‎headquarters, legal address and location of the industrial activity shall be ‎the following address: Factory 1 in the city of Tenth of Ramadan, plot XIIB ‎in the industrial zone B1 with an area of 86,266 square meters and 95 cm ‎and its extension Factory 2 plot No. Extension B1 with an area of 29,977 ‎square meters and its extension Factory 3 extension B1 plot No. 49 and 50 ‎with an area of 10,344 square meters and 64 cm......etc., in the Egyptian ‎Securities Registration Table - Shares.‎

Fifth: - Imposing a financial obligation on the company in the amount of 10 thousand Egyptian pounds, due to its violation of the provisions of Article (26) of the rules for listing and delisting securities on the Egyptian Stock Exchange and Article (26) of its executive procedures, in accordance with the contract regulating the listing of securities on the Egyptian Stock Exchange tables concluded with the company, with the company being granted a grace period of 15 days to pay the financial obligation starting from the date of notification of the Listing Committee’s decision.